Page last updated: 2024-12-05
dibromsalicil
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
dibromsalicil: brominated salicyclic acid deriv; antiplaque antiseptic [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 10662 |
| CHEMBL ID | 366205 |
| SCHEMBL ID | 2156880 |
| MeSH ID | M0062082 |
Synonyms (47)
| Synonym |
|---|
| fungotox (van) |
| 5,5'-dibromo-2,2'-dihydroxybibenzoyl |
| 5,5'-dibrom-2,2'-dioxybenzil [german] |
| bis(5-bromo-2-hydroxyphenyl)ethanedione |
| salicil, 5,5'-dibromo- |
| brn 3384611 |
| einecs 208-351-3 |
| nsc 13235 |
| 5,5'-dibromo-2,2'-dihydroxybenzil |
| z2v3ff4b7f , |
| 5,5'-dibrom-2,2'-dioxybenzil |
| unii-z2v3ff4b7f |
| benzil-based compound, 31 |
| bdbm22753 |
| 1,2-bis(5-bromo-2-hydroxyphenyl)ethane-1,2-dione |
| cid_10662 |
| mls002638309 , |
| respectol |
| dibromsalicil |
| dibrosil |
| 5,2'-dihydroxybenzil |
| degermon |
| fungotox |
| dibromosalicil |
| 5,2'-dioxybenzil |
| dibromosalicyl |
| 5,5'-dibromosalicil |
| 523-88-6 |
| nsc13235 |
| nsc-13235 |
| 5,2'-dihydroxybibenzoyl |
| ethanedione, bis(5-bromo-2-hydroxyphenyl)- |
| wln: qr de bvvr bq ee |
| salicil,5'-dibromo- |
| dibrosal |
| 1,2-bis(5-bromo-2-hydroxy-phenyl)ethane-1,2-dione |
| smr001547796 |
| CHEMBL366205 |
| HMS3086D19 |
| SCHEMBL2156880 |
| dibromsalicil [mi] |
| bis-(5-brom-2-hydroxyphenyl)ethandion |
| DTXSID20200328 |
| 1,2-bis(5-bromo-2-hydroxyphenyl)-1,2-ethanedione |
| AKOS027382229 |
| Q27294920 |
| PD129618 |
Research Excerpts
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (29)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 63.0957 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 7.0795 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
| TDP1 protein | Homo sapiens (human) | Potency | 21.8528 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| Smad3 | Homo sapiens (human) | Potency | 6.4083 | 0.0052 | 7.8098 | 29.0929 | AID588855; AID720534; AID720536; AID720537 |
| PINK1 | Homo sapiens (human) | Potency | 11.2202 | 2.8184 | 18.8959 | 44.6684 | AID624263 |
| 67.9K protein | Vaccinia virus | Potency | 15.5864 | 0.0001 | 8.4406 | 100.0000 | AID720579; AID720580 |
| Parkin | Homo sapiens (human) | Potency | 11.2202 | 0.8199 | 14.8306 | 44.6684 | AID624263 |
| IDH1 | Homo sapiens (human) | Potency | 3.6626 | 0.0052 | 10.8652 | 35.4813 | AID686970 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 50.1187 | 0.0060 | 26.1688 | 89.1251 | AID540317 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 7.9433 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
| importin subunit beta-1 isoform 1 | Homo sapiens (human) | Potency | 32.6427 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
| snurportin-1 | Homo sapiens (human) | Potency | 32.6427 | 5.8048 | 36.1306 | 65.1308 | AID540253 |
| GTP-binding nuclear protein Ran isoform 1 | Homo sapiens (human) | Potency | 32.6427 | 5.8048 | 16.9962 | 25.9290 | AID540253 |
| geminin | Homo sapiens (human) | Potency | 9.4765 | 0.0046 | 11.3741 | 33.4983 | AID624296; AID624297 |
| Glycoprotein hormones alpha chain | Homo sapiens (human) | Potency | 28.1838 | 4.4668 | 8.3448 | 10.0000 | AID624291 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 0.8913 | 0.5623 | 9.3985 | 25.1189 | AID652106 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 17.5855 | 1.9953 | 25.5327 | 50.1187 | AID624287; AID624288 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 0.8913 | 1.7783 | 16.2081 | 35.4813 | AID652104 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 44.6684 | 3.9811 | 46.7448 | 112.2020 | AID720708 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| galanin receptor type 3 | Homo sapiens (human) | IC50 (µMol) | 1.1020 | 0.0066 | 1.5431 | 7.3650 | AID687013 |
| exodeoxyribonuclease V subunit RecB | Escherichia coli str. K-12 substr. MG1655 | IC50 (µMol) | 118.5380 | 0.1000 | 0.1000 | 0.1000 | AID652151 |
| exodeoxyribonuclease V subunit RecC | Escherichia coli str. K-12 substr. MG1655 | IC50 (µMol) | 118.5380 | 0.1000 | 0.1000 | 0.1000 | AID652151 |
| Cocaine esterase | Homo sapiens (human) | Ki | 0.0727 | 0.0063 | 0.9835 | 8.0000 | AID239272 |
| Coagulation factor XII | Homo sapiens (human) | Ki | 60.0252 | 0.0025 | 1.8669 | 7.2500 | AID1798224 |
| Cholinesterase | Homo sapiens (human) | Ki | 66.6877 | 0.0000 | 1.5173 | 9.7300 | AID1798224; AID239166 |
| Liver carboxylesterase 1 | Oryctolagus cuniculus (rabbit) | Ki | 50.0300 | 0.0136 | 1.7025 | 7.2500 | AID1798224; AID239167 |
| Acetylcholinesterase | Homo sapiens (human) | Ki | 66.6877 | 0.0000 | 1.2786 | 9.7300 | AID1798224; AID239122 |
| Liver carboxylesterase 1 | Homo sapiens (human) | Ki | 66.6877 | 0.0025 | 2.0136 | 8.4800 | AID1798224; AID239197 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (174)
Molecular Functions (60)
Ceullar Components (49)
Bioassays (17)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID1798224 | Enzyme Inhibition Assay from Article 10.1021/jm049011j: \\Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases.\\ | 2005 | Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8 | Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. |
| AID239167 | Inhibition constant against rabbit liver carboxylesterase (rCE) using nitrophenyl acetate (o-NPA) as substrate | 2005 | Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8 | Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. |
| AID239122 | Inhibition constant against human Acetylcholinesterase (hAcChE) using acetylthiocholine (AcTCh) as substrate | 2005 | Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8 | Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. |
| AID239272 | Inhibition constant against human intestinal carboxylesterase 2 (hiCE) using nitrophenyl acetate (o-NPA) as substrate | 2005 | Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8 | Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. |
| AID239197 | Inhibition constant against human liver carboxylesterase 1 (hCE1) using nitrophenyl acetate (o-NPA) as substrate | 2005 | Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8 | Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. |
| AID239166 | Inhibition constant against human Butyrylcholinesterase (hBuChE) using butyrylthiocholine (BuTCh) as substrate | 2005 | Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8 | Identification and characterization of novel benzil (diphenylethane-1,2-dione) analogues as inhibitors of mammalian carboxylesterases. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.19
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.19) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||